297 related articles for article (PubMed ID: 22208431)
1. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.
Amerio P; Amoruso G; Bardazzi F; Campanati A; Cassano N; Conti A; Gisondi P; Guarneri C; Mazzotta A; Piaserico S; Prestinari F; Prignano F; Zane C; de Simone C
J Dermatolog Treat; 2013 Aug; 24(4):305-11. PubMed ID: 22208431
[TBL] [Abstract][Full Text] [Related]
2. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
[TBL] [Abstract][Full Text] [Related]
3. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.
Sauzullo I; Mengoni F; Marocco R; Potenza C; Skroza N; Tieghi T; Lichtner M; Vullo V; Mastroianni CM
Br J Dermatol; 2013 Nov; 169(5):1133-40. PubMed ID: 23909256
[TBL] [Abstract][Full Text] [Related]
4. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients.
Sánchez-Moya AI; Dauden E
J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):730-3. PubMed ID: 21564322
[TBL] [Abstract][Full Text] [Related]
5. Severe psoriasis with positive tuberculosis test and treatment with biologic therapy: a case report.
Skroza N; Proietti I; Bernardini N; La Viola G; Nicolucci F; Tolino E; Zuber S; Potenza C
Cutis; 2012 Sep; 90(3):120-2. PubMed ID: 23094309
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.
Chiu HY; Hsueh PR; Tsai TF
Br J Dermatol; 2011 Mar; 164(3):553-9. PubMed ID: 21083541
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment.
Nordgaard-Lassen I; Dahlerup JF; Belard E; Gerstoft J; Kjeldsen J; Kragballe K; Ravn P; Sørensen IJ; Theede K; Tjellesen L;
Dan Med J; 2012 Jul; 59(7):C4480. PubMed ID: 22759856
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
Medina-Gil C; Dehesa L; Vega A; Kerdel F
Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
[TBL] [Abstract][Full Text] [Related]
9. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
Nisar MK; Rafiq A; Östör AJ
Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
[TBL] [Abstract][Full Text] [Related]
10. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
[TBL] [Abstract][Full Text] [Related]
11. The risk of tuberculosis in patients treated with TNF antagonists.
Salgado E; Gómez-Reino JJ
Expert Rev Clin Immunol; 2011 May; 7(3):329-40. PubMed ID: 21595599
[TBL] [Abstract][Full Text] [Related]
12. Is tuberculin skin testing reliable during anti-tumor necrosis factor-alfa therapy? A case report and review of the literature.
Haddican MM; Koo JY
J Am Acad Dermatol; 2011 Jul; 65(1):195-7. PubMed ID: 21507516
[TBL] [Abstract][Full Text] [Related]
13. Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy.
Gisondi P; Pezzolo E; Lo Cascio G; Girolomoni G
Br J Dermatol; 2014 Oct; 171(4):884-90. PubMed ID: 24863903
[TBL] [Abstract][Full Text] [Related]
14. [The relevance of diagnostic criteria for latent tuberculosis before initiation of TNF-alpha inhibitors in psoriasis patients].
Goujon C; Gormand F; Gunera-Saad N; Dahel K; Vial T; Nicolas JF
Ann Dermatol Venereol; 2010; 137(6-7):437-43. PubMed ID: 20620572
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers.
Saraceno R; Specchio F; Chiricozzi A; Sarmati L; Amicosante M; Chimenti MS; Chimenti S
Expert Opin Biol Ther; 2014 Feb; 14(2):151-6. PubMed ID: 24303977
[TBL] [Abstract][Full Text] [Related]
16. Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People's Republic of China.
Li CR; Mao QX; Chen M; Jia WX; Yao X; Feng SY; Jia H; Gong JQ; Yang XY
Drug Des Devel Ther; 2015; 9():5591-4. PubMed ID: 26508833
[TBL] [Abstract][Full Text] [Related]
17. Risk of tuberculosis with the use of anti-TNF medications in psoriasis: incidence, screening and management.
Kasiraman V; Atwan AA; Durojaiye OC; Kalavala M; Piguet V
Dermatol Online J; 2014 Aug; 20(8):. PubMed ID: 25148273
[TBL] [Abstract][Full Text] [Related]
18. Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis.
Tan X; Balkrishnan R; Feldman SR
J Drugs Dermatol; 2013 Mar; 12(3):e41-5. PubMed ID: 23545925
[TBL] [Abstract][Full Text] [Related]
19. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.
Mariette X; Baron G; Tubach F; Lioté F; Combe B; Miceli-Richard C; Flipo RM; Goupille P; Allez M; Salmon D; Emilie D; Carcelain G; Ravaud P
Ann Rheum Dis; 2012 Nov; 71(11):1783-90. PubMed ID: 22258485
[TBL] [Abstract][Full Text] [Related]
20. Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis.
Capo A; Di Nicola M; Auriemma M; Piaserico S; Cuccurullo C; Santilli F; Davi G; Amerio P
Eur J Dermatol; 2014; 24(1):133-5. PubMed ID: 24589526
[No Abstract] [Full Text] [Related]
[Next] [New Search]
